Product Description
Brand Boditech
Sample Type Serum/ Plasma/ WB
SMFP-74 24T
CAT No SMFP-75
Biomarker Therapeutic Drug Monitoring
Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Infliximab allows for reliable measurement of Infliximab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Infliximab immediately before the next administration.
Precise Therapeutic Drug MonitoringThe AFIAS Infliximab test delivers clinically validated, quantitative measurement of infliximab levels in serum. This enables healthcare providers to effectively monitor therapy, ensure optimal dosing, and enhance patient outcomes. The assay is highly reliable due to its fluorescence-based detection and analyzer-driven calibration.
Rapid, Easy, and Reliable OperationWith a turnaround time of only 10-20 minutes, the AFIAS Infliximab cartridge lets laboratories act quickly. Designed for ease of handling, the single-use kit minimizes risks of cross-contamination and user error. Automated calibration ensures high consistency, while digital output makes interpretation straightforward.
Seamless AFIAS System CompatibilityEngineered for exclusive use with Boditech AFIAS analyzers, the cartridge integrates smoothly into your existing workflow. Each cartridge features barcode-based traceability and is stored at 2-8C for longevity. Compact and portable, the test supports flexible laboratory practice while upholding rigorous diagnostic standards.
FAQ's of Boditech AFIAS Infliximab:
Q: How does the Boditech AFIAS Infliximab test work?
A: The AFIAS Infliximab test employs a fluorescent-labeled antibody to quantitatively measure infliximab levels in serum. Once the sample is added to the cartridge and inserted into a compatible Boditech AFIAS Analyzer, the system automatically calibrates via cartridge barcode and provides digital results within 10-20 minutes.
Q: What are the main benefits of using the AFIAS Infliximab cartridge for drug monitoring?
A: This single-use, quantitative cartridge provides rapid, accurate results, supports precise therapeutic management, simplifies workflow with auto-calibration, and reduces cross-contamination risks. Its digital output ensures easy integration with laboratory processes and enhanced decision-making for infliximab therapy adjustments.
Q: When and where should the AFIAS Infliximab test be used?
A: The test is intended for laboratory use to monitor serum infliximab levels in patients undergoing Remicade therapy. It is suitable when timely dose adjustments are required for optimal therapeutic outcomes, and is designed exclusively for use in conjunction with the Boditech AFIAS Analyzer.
Q: What components are included in the AFIAS Infliximab kit?
A: Each kit contains a single-use test cartridge, buffer, desiccant pouch, and instruction leaflet. The cartridge is individually foil-packed and features a barcode for lot traceability. An AFIAS Analyzer instrument is required for processing the test.
Q: How should the AFIAS Infliximab test cartridge be stored and handled?
A: Store the cartridge at 2-8C and protect it from direct sunlight. Allow the cartridge to reach room temperature before use, and ensure it is not expired by checking the shelf life as indicated by the manufacturer.
Q: What is the detection principle and how is accuracy assured?
A: The test operates on the Fluorescent ImmunoAssay (FIA) principle, using fluorescent-labeled antibodies specific for infliximab. Accuracy and sensitivity are clinically validated, with automated instrument calibration ensuring consistent and reliable results.